Search
Pfizer has affirmed that the US Food and Drug Administration (FDA) is contemplating the withdrawal of the Emergency Use Authorization (EUA) for its COVID-19 vaccine in healthy children under the age of five. This potential decision indicates that many young children may lose access to this vaccine, especially considering the even more restricted availability of Moderna and Novavax vaccines for this age group. Although COVID-19 symptoms are generally mild in most children, infants under one year and children with certain medical conditions remain at heightened risk of severe illness and hospitalization. Pfizer has requested to maintain the authorization through the fall and winter seasons and is engaging with the FDA to explore solutions, underscoring that the review does not pertain to the vaccine's safety or efficacy.
-
C114 Communication Network -
Communication Home
